The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA.

Appl Health Econ Health Policy

Department of Emergency Medicine, Northwestern University, Chicago, IL, USA.

Published: January 2024

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40258-023-00840-6DOI Listing

Publication Analysis

Top Keywords

inflation reduction
4
reduction hope
4
hope prescription
4
prescription drug
4
drug prices
4
prices usa
4
inflation
1
hope
1
prescription
1
drug
1

Similar Publications

The economic feasibility of low-carbon ammonia production pathways, such as steam methane reforming with carbon capture and storage, biomass gasification, and electrolysis, is assessed under various policy frameworks, including subsidies, carbon pricing, and renewable hydrogen regulations. Here, we show that employing a stochastic techno-economic analysis at the plant level and a net present value approach under the US Inflation Reduction Act reveals that carbon capture and biomass pathways demonstrate strong economic potential due to cost-effectiveness and minimal public support needs. Conversely, the electrolytic pathway faces significant economic challenges due to higher costs and lower efficiency.

View Article and Find Full Text PDF

Remote Ischemic Preconditioning (RIPC) is a therapy characterized by repeated bouts of limb ischemia and reperfusion. RIPC protects against ischemia-reperfusion injury (IRI), and preclinical studies suggest that this is mediated through release of endogenous opioids. We aimed to interrogate the role of endogenous opioids in RIPC-signaling in humans, using an arm model of IRI.

View Article and Find Full Text PDF

Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation.

J Comp Eff Res

January 2025

Boston Scientific Corporation; 100 Boston Scientific Way, Marlborough, MA, USA.

This study assessed the economic impact of reducing one postoperative visit following inflatable penile prosthesis (IPP) implantation. Scenario analyses were used to model the effects of eliminating one 30-min IPP postoperative visit from the expected 2.5 visits accounted for by the American Medical Association resource-based relative value scale data.

View Article and Find Full Text PDF

Objective: Identify differences in Medicare reimbursement changes for general otolaryngology, pediatric otolaryngology, head and neck oncology, laryngology, rhinology, otology, facial plastic and reconstructive surgery, and sleep surgery subspecialties from 2013 to 2024.

Methods: Subspecialty-based procedures' facility prices and relative value units (RVUs) were sourced from the Centers for Medicare & Medicaid Services' Physician Fee Schedule. Prices were adjusted for inflation, and the average percent change in facility price and RVUs for each subspecialty was calculated.

View Article and Find Full Text PDF

Introduction: The 2022 Inflation Reduction Act is expected to result in lower drug prices for Medicare beneficiaries in the United States (US). The Centers for Medicare & Medicaid Services (CMS) released the most recent draft guidance for the medicare drug price negotiation (DPN) program in May 2024.

Areas Covered: In August 2023, the list of 10 drugs selected for the DPN were published and the first round of negotiations are now complete.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!